Alnylam Pharmaceuticals, Inc.

ALNY

US02043Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-25 EDT			5-day change	1st Jan Change
240.2 ^USD	+7.74%		+56.08%	+25.46%

06-25	Sector Update: Health Care Stocks Ease Late Afternoon	MT
06-25	Alnylam Pharmaceuticals Shares Rise as Heart Disease Candidate Meets Primary Endpoint in Late-Stage Study	MT

Alnylam Pharmaceuticals Inc Wins A Federal Contract from the U.S Department of Veterans Affairs

January 11, 2019 at 02:23 pm

Alnylam Pharmaceuticals Inc. won a $4,149,600 federal contract from the U.S. Department of Veterans Affairs for drugs, pharmaceuticals and hematology products for the VA National Acquisition Center.

Latest news about Alnylam Pharmaceuticals, Inc.

Sector Update: Health Care Stocks Ease Late Afternoon	06-25	MT
Alnylam Pharmaceuticals Shares Rise as Heart Disease Candidate Meets Primary Endpoint in Late-Stage Study	06-25	MT
TD Cowen Adjusts Price Target on Alnylam Pharmaceuticals to $282 From $260, Maintains Buy Rating	06-25	MT
Barclays Raises Price Target on Alnylam Pharmaceuticals to $291 From $236, Maintains Overweight Rating	06-25	MT
Wells Fargo Raises Price Target on Alnylam Pharmaceuticals to $207 From $161, Maintains Equalweight Rating	06-25	MT
Out with AI, in with defensive stocks	06-25
Morgan Stanley Raises Alnylam Pharmaceuticals Price Target to $250 From $164, Maintains Equal Weight Rating	06-25	MT
Evercore ISI Boosts Price Target on Alnylam Pharmaceuticals to $260 From $210, Keeps Outperform Rating	06-25	MT
Chardan Raises Price Target on Alnylam Pharmaceuticals to $265 From $225, Keeps Buy Rating	06-25	MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $250 From $235, Keeps Outperform Rating	06-25	MT
ANALYST RECOMMENDATIONS : Capri Holdings, Adobe, Broadcom, Celanese, Admiral...	06-25
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	06-24	MT
Top Midday Gainers	06-24	MT
Alnylam Pharmaceuticals Says Heart Disease Therapy Meets Primary Endpoint in Late-Stage Study	06-24	MT
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call	06-24
Alnylam's heart disease drug meets main goal in late-stage study	06-24	RE
Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations	06-24	CI
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,224,546, According to a Recent SEC Filing	06-03	MT
HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating	05-07	MT
Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed	05-02	MT
Transcript : Alnylam Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Earnings Flash (ALNY) ALNYLAM PHARMACEUTICALS Posts Q1 Revenue $494.3M, vs. Street Est of $426.9M	05-02	MT
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024	05-02	CI
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of Their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in Additional Latam and APAC Markets Including Australia	04-30	CI

Chart Alnylam Pharmaceuticals, Inc.

Duration

Period

More charts

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Sector

Biotechnology & Medical Research

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Alnylam Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

240.2 USD

Average target price

243.6 USD

Spread / Average Target

+1.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	30.38B
MODERNA, INC.	+38.36%	52.73B
LONZA GROUP AG	+38.65%	39B
IQVIA HOLDINGS INC.	-8.63%	38.52B
CELLTRION, INC.	-11.17%	26.39B
ICON PUBLIC LIMITED COMPANY	+11.44%	26.08B
UNITED THERAPEUTICS CORPORATION	+45.09%	14.15B
MEDPACE HOLDINGS, INC.	+32.93%	12.6B
BIO-TECHNE CORPORATION	-5.30%	11.51B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.69%	10.63B

Other Biotechnology & Medical Research